Anastasia Valerievna Fedorova

Anastasia Valerievna Fedorova

Auto-generated profile, based on publicly available information

Anastasia Valerievna Fedorova

Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
PSPavel A. Shesternya
Pavel A. Shesternya
AZAlena I. Zagrebneva
Alena I. Zagrebneva
OAO. V. Antipova
O. V. Antipova
YAYu. V. Arbuzova
Yu. V. Arbuzova
IBI. G. Bannikova
I. G. Bannikova
ALAleksandr M Lila
Aleksandr M Lila
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.

14 June 2024 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
AFA. V. Fedorova
A. V. Fedorova
NBN. E. Banshchikova
N. E. Banshchikova
ASAlexey Sizikov
Alexey Sizikov
AMA. A. Mullagaliev
A. A. Mullagaliev
ELE. A. Letyagina
E. A. Letyagina
MKMaksim Korolev
Maksim Korolev
In the context of the new coronavirus infection (NCI) COVID-19 pandemic, the rheumatological community is facing new challenges in the treatment of immune-inflammatory rheumatic diseases (IIRDs). It has been shown that rheumatological patients have an increased risk of infections and a severe course of NCI and that IIRD therapy also influences the disease outcomes. In particular, the use of the anti-B-cell medication rituximab (RTM) is associated with a higher risk of severe NCI and increased mortality. The COVID-19 pandemic has highlighted the need to find alternative and safe treatment options for these patients. This work is the continuation of a 12-week study on the efficacy and safety of olok-izumab (OKZ) therapy in patients with rheumatoid arthritis (RA) after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic.   Objective: to evaluate the efficacy and safety of OKZ (Artlegia®; solution for subcutaneous administration, 160 mg/ml – 0.4 ml) for the treatment of patients with RA in real-life clinical practice after switching from RTM during the COVID-19 pandemic.   Material and methods. The study included 19 patients with a confirmed diagnosis of RA who had received RTM at a dose of 500–1000 mg twice every 14 days at least 6 months ago. As disease activity increased, RTM was replaced with OKZ while therapy with synthetic disease-modifying anti-rheumatic drugs (DMARDs) was continued. At weeks 0, 4, 8, 12 and 24 after switching the biologic DMARD, the number of tender (TJN) and swollen (SJN) joints out of 28, pain intensity on a visual analogue scale, ESR, CRP level, disease activity indices CDAI, DAS28-ESR, DAS28-CRP, HAQ index and the safety profile of the therapy were assessed at each visit.   Results and discussion. After 4, 8, 12 and 24 weeks of OKZ administration, there was a statistically significant decrease in mean TJN (from 10 to 6.0, 3.0, 5.0 and 4.0, respectively; p < 0.05) and SJN (from 7.0 to 3.0 by week 4 and to 2.0 by weeks 8, 12 and 24; p < 0.05). At the same time, a decrease in CRP and ESR values was also observed: median CRP decreased from 18 to 0.6 mg/l by week 4 and to 0.5 mg/l by weeks 8, 12 and 24 (p < 0.05), ESR from 30 to 5 mm/h in each study period (p < 0.05). CRP levels normalized by week 4, regardless of baseline values. All RA activity indices showed a positive dynamic compared to baseline values from week 4 onwards in each assessment period. After weeks 4, 8, 12 and 24, the median DAS28-ESR decreased from 5.50 to 3.57; 3.30; 3.08 and 3.01 (p < 0.05); DAS28-CRP – from 5.30 to 3.46; 3.23; 3.26 and 3.12 (p < 0.05); CDAI – from 27.0 to 17.0; 12.0; 15.0 and 12.0 (p < 0.05), respectively. All patients showed a decrease in pain by the 4th week of observation. A statistically significant improvement in functional status was observed after the 4th week of therapy and was maintained until week 24. The median HAQ index decreased from 1.62 to 1.50 at weeks 4, 8 and 12 and to 1.12 at week 24 (p < 0.05).   Conclusion. The study showed that the non-medical switch from RTM to OKZ during the COVID-19 pandemic was effective and safe.

27 June 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AMA. Yu. Morenkova
A. Yu. Morenkova
TTTamara Tyrinova
Tamara Tyrinova
AFA. V. Fedorova
A. V. Fedorova
MTM. A. Tikhonova
M. A. Tikhonova
НИН. А. Ильина
Н. А. Ильина
ECE. R. Chernykh
E. R. Chernykh
Aim – to evaluate myeloid-derived suppressor cell (MDSC) subset counts and their suppressor potential in axial spondyloarthritis (axSpA) patients, as well as to analyze changes in the studied parameters in biological therapy (BT).Materials and methods. The study included 50 axSpA patients receiving 1st line therapy (non-steroidal anti-inflammatory drugs ±sulfasalazine/methotrexate) and 44 ageand sex-related healthy donors. Eight patients were initiated with BT (TNFαor IL-17 inhibitors). Peripheral blood granulocytic (G-MDSC), monocytic (M-MDSC) MDSCs, early-stage differentiation MDSCs (E-MDSC), and inhibitory molecule expression (PDL1, Arg-1, and IDO) were evaluated by flow cytometry.Results. The axSpA patients were characterized by increased G-MDSC counts (р<0.01), particularly manifested with high disease activity. Axial manifestation was associated with a combination of increased G-MDSC and E-MDSC numbers (р<0.05). The extra-axial group showed an isolated increase in G-MDSC (р<0.05), whereas coxitis was associated with an increase in both G-MDSC and M-MDSC (р<0.05). Low activity was associated with an isolated M-MDSC increase (р=0.045). Patients had reduced expression of majority of the studied suppressor molecules in MDSCs. Axial manifestation was characterized by a decreased expression of PDL1 and IDO in G-MDSCs and E-MDSCs (р<0.05), as well as Arg-1 in E-MDSCs and M-MDSCs (р<0.05). Patients with extra-axial manifestations (including coxitis) exhibited the most significant reduction in the expression of all three inhibitory molecules in M-MDSCs. High activity was associated with a decrease in PDL1+ G-MDSCs and E-MDSCs (р<0.05), as well as Arg-1and IDO-expressing M-MDSCs (р<0.05). In low disease activity, most of the analyzed parameters did not differ significantly from donor values, with the exception of a reduced Arg-1+ M-MDSC frequency (р=0.04). BT reduced G-MDSC counts in 75% of patients to levels comparable to those of healthy donors.Conclusion. Despite the reduced suppressor potential of MDSCs, patients undergoing first-line therapy with high activity demonstrated increased G-MDSC counts, while low activity axSpA was characterized by an isolated increase in M-MDSCs. The BT administration blocked G-MDSC accumulation.


20 December 2025 in Medical Immunology (Russia)
Verified
Journal Article
Closed access
ESEkaterina Ya. Shevela
Ekaterina Ya. Shevela
LSLudmila Sakhno
Ludmila Sakhno
MTM. A. Tikhonova
M. A. Tikhonova
TTTamara Tyrinova
Tamara Tyrinova
AMA. Yu. Morenkova
A. Yu. Morenkova
ECE. R. Chernykh
E. R. Chernykh
Regulation of inflammation events in inflammatory/autoimmune rheumatic diseases, particularly axial spondyloarthritis, is critically important for alleviating clinical symptoms. Recent studies have shown the key role of PD-1 and Tim-3 inhibitory receptors in regulating the functional phenotype of monocytes in inflammatory/autoimmune diseases. The aim of this study was to investigate the expression of the PD-1 and Tim-3 inhibitory receptors in different subsets of monocytes in patients with axial spondyloarthritis (axSpA), and to evaluate their association with clinical features, as well as with tolerogenic marker Mer tyrosine kinase (MerTK). The expression of PD-1 and Tim-3 in classical, intermediate, and non-classical monocytes was determined by means of multicolor flow cytometry in peripheral blood mononuclear cells in 60 patients with axial spondyloarthritis and 40 healthy donors. The analysis of circulating monocyte subpopulations revealed an increased proportion of classical monocytes in patients, which positively correlated with systemic inflammation markers: erythrocyte sedimentation rate and C-reactive protein. Like as in donor group, the highest expression of PD-1 and Tim-3 in axSpA patients was observed in intermediate and non-classical monocyte subsets. However, the relative proportions of PD-1 + and PD-1 + Tim-3 + cells in intermediate and non-classical monocytes were significantly decreased in axSpA patients, whereas Tim-3 expression levels did not differ from the donor values. Notably, the proportion of PD-1 + cells directly correlated with expression of MerTK, a factor mediating the anti-inflammatory activity of monocytes/macrophages in all monocyte subsets. A statistically significant decrease in PD-1 expression and co-expression of PD-1 and Tim-3 was detected in HLA-B27 antigen carriers, patients with advanced and late-stage disease, and those with peripheral axSpA, including hip joint involvement. On the contrary, in HLA-B27-negative patients and those with early/non-radiographic stage disease, PD-1 expression was comparable to donor levels, while Tim-3 + cell contents were increased among classical monocytes. In patients receiving first-line therapy, the decreased PD-1 expression and PD-1 + Tim-3 + co-expression directly correlated with disease activity. The obtained data that include a reduced PD-1 expression and PD-1 + Tim-3 + co-expression in intermediate and non-classical monocytes in patients with genetic predisposition, advanced disease stages, and peripheral joint involvement, as well as the association between PD-1 + cell number and MerTK expression in all monocyte subsets, suggest a dysregulation of inhibitory checkpoint receptor expression under inflammatory conditions. These findings could presume a diminished anti-inflammatory capacity of monocytes.